NASDAQ · AARD
Healthcare · Biotechnology
$5.53
Up+$0.38 (+7.38%)
Updated Sep 18, 2026, 2:17 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AARD closed at $5.53 after 20 trading sessions, down 6.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $5.32 | $5.77 | $5.19 | $5.53 | 258.08K |
| Sep 16, 2026 | $5.04 | $5.29 | $4.93 | $5.15 | 47.91K |
| Sep 15, 2026 | $5.47 | $5.545 | $5.01 | $5.02 | 64.15K |
| Sep 14, 2026 | $4.90 | $5.88 | $4.80 | $5.55 | 216.86K |
| Sep 11, 2026 | $5.11 | $5.54 | $4.975 | $5.13 | 276.57K |
| Sep 10, 2026 | $4.87 | $5.015 | $4.54 | $5.01 | 209.38K |
| Sep 9, 2026 | $5.33 | $5.456 | $4.895 | $4.92 | 109.95K |
| Sep 8, 2026 | $5.33 | $5.71 | $5.10 | $5.33 | 164.75K |
| Sep 4, 2026 | $5.72 | $5.991 | $5.15 | $5.38 | 257.81K |
| Sep 3, 2026 | $5.92 | $6.19 | $5.60 | $5.73 | 89.32K |
| Sep 2, 2026 | $6.05 | $6.225 | $5.795 | $5.95 | 59.41K |
| Sep 1, 2026 | $6.00 | $6.245 | $5.807 | $5.92 | 85.01K |
| Aug 31, 2026 | $5.70 | $6.155 | $5.30 | $6.10 | 125.44K |
| Aug 28, 2026 | $6.47 | $6.47 | $5.62 | $5.79 | 143.1K |
| Aug 27, 2026 | $6.89 | $7.085 | $6.585 | $6.62 | 74.26K |
| Aug 26, 2026 | $7.29 | $7.30 | $6.21 | $6.81 | 111.94K |
| Aug 25, 2026 | $6.94 | $7.31 | $6.49 | $7.25 | 145.2K |
| Aug 24, 2026 | $6.75 | $6.97 | $6.2826 | $6.88 | 83.3K |
| Aug 21, 2026 | $5.91 | $6.90 | $5.80 | $6.82 | 173.69K |
| Aug 20, 2026 | $6.76 | $7.12 | $5.76 | $5.89 | 250.19K |
The latest Smart Investors Daily articles mentioning AARD.
AARD research
Company profile and research snapshot.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 20, 2026 | HC Wainwright & Co. | Neutral | — |
| May 15, 2026 | Morgan Stanley | Underweight | — |
| May 15, 2026 | B. Riley Securities | Buy | — |
| May 15, 2026 | BTIG | Neutral | — |
| Mar 24, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 20, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and announces $6 price target.
Benzinga · Mar 4, 2026
Aardvark Therapeutics pauses Phase 3 HERO trial after cardiac safety observations, sending shares down nearly 61%.
Benzinga · Mar 2, 2026
Benzinga · Mar 2, 2026
Dow Jones down 0.46% amid Iran-U.S. conflict, NASDAQ down 0.22% and S&P 500 down 0.39%. Energy sector up 1.8%, consumer discretionary down 1.7%. Sealed Air Corp beats earnings expectations. The Dow Jones is down 0.46%, NASDAQ is down 0.22%, and S&P 500 is down 0.39%. Energy sector up 1.8% while consumer discretionary is down 1.7%. Sealed Air Corp surpasses earnings expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AARD.
